source
- Resilience and Eli Lilly commit $750 million to expand Cincinnati GLP-1 injectable productionResilience and Eli Lilly announced a joint $750 million investment to expand drug manufacturing capacity in Cincinnati. The expansion will add at least 400 jobs and increase Resilience's workforce…
- Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trialNovo Nordisk reported that its investigational anti‑inflammatory antibody, ziltivekimab, did not reduce the incidence of major cardiovascular events in a pivotal Phase 3 study. The trial enrolled…